Anika Therapeutics (ANIK) Stock Statistics & Valuation Metrics

Anika Therapeutics has a market cap or net worth of $162.20M. The enterprise value is $129.82M.

Anika Therapeutics has 14,341,423 shares outstanding. The number of shares has decreased by -2.65% in one year.

Anika Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -8.98%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.

In the last 12 months, operating cash flow was 5.40M and capital expenditures -8.75M, giving a free cash flow of -3.35M billion.

Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Anika Therapeutics upcoming earnings date is Jul 30, 2025, After Close (Confirmed).

Anika Therapeutics as a current ratio of 4.88, with Debt / Equity ratio of 17.14%

In the past 12 months, Anika Therapeutics has paid 6.06M in taxes.

Anika Therapeutics EV to EBITDA ratio is 70.40, with an EV/FCF ratio of -91.21.

Anika Therapeutics has $53.37M in cash and marketable securities with $25.44M in debt, giving a net cash position of -$27.93M billion.

Gross margin is 62.58%, with operating margin of -4.25%, and net profit margin of -47.02%.

The average price target for Anika Therapeutics is $21.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy